MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?

Cancer Immunology, Immunotherapy : CII. 2014 September 19. [Epub ahead of print] [Link]

Calabro L, Ceresoli GL, di Pietro A, Cutaia O, Morra A, Ibrahim R, Maio M.

Abstract

No second-line treatment significantly prolongs the survival of malignant mesothelioma patients who have a high unmet medical need. Here, we comment on the therapeutic potential of cytotoxic T-lymphocyte-associated protein (CTLA)4-blockade by the anti-CTLA4 monoclonal antibody (mAb) tremelimumab of refractory malignant mesothelioma patients. We also focus on the critical role of an accurate tumor assessment in the course of treatment with immunomodulating mAb. Finally, treatment with potentially effective, second-generation checkpoint(s) inhibiting mAb, as well future combination strategies in this deadly disease, will be discussed.

Both comments and trackbacks are currently closed.